IEsohunter

Plasma DNA Methylation Detection Kit for Esophageal Cancer

0 %

Sensitivity

0 %

Specificity

0 %

The sensitivity of high-grade intraepithelial neoplasia

Early detection is the key to the prevention and treatment of esophageal cancer. The early 5-year survival rate can reach 95%.

Esophageal cancer is the 8th most common cancer worldwide, and the 6th most common cause of cancer related deaths.

80% of esophageal cancers occur in develop-ing countries and Esophageal squamous cell cancer (ESCC) is the predominant histological subtype. In Western countries, esophageal adenocarcinoma (EAC) is the most common histological subtype of esophageal cancer.

Endoscopy is the gold standard for esopha-geal cancer screen-ing, but acceptance is low.

Non-invasive sampling, blood ctDNA carries a variety of tumor genetic information such as methylation, and has been used in clinical applications such as early tumor screening.

The Advantage of IEsohunter

Non-invasive

Use blood as sample, No need for invasive endoscopy screening.

Comprehensive

Detect both esophageal squamous cell carcinoma and esophageal adenocarci-noma

Efficient

Results available within 4.5h since sample processing.

Accurate

Sensitivity for esophageal squamous cell carcinoma is 87.27%. Sensitivity for precancerous lesion is 41.38%. Specificity is 93.17%.

Creative

The first DNA methylation product for esophageal cancer detection, adopt unique Methylation Navigation Technology(DMLT) and Methylation PCR Sensitization Technology(SEM-PCR).

Kit Components of IEsohunter

Brand Name	IEsohunter
Packing	24tests/kit, 96tests/kit
Specimen	Plasma
Sample volume	10mL
Intended Use	This kit is intended for the qualitative detection of methylated KCNA3 and OTOP2 of cfDNA in peripheral blood plasma of individuals at high risk of esophageal cancer.